

Supplementary Table 3. Summary of immunogenicity results for the per-protocol set

	hSBA			rSBA			
	No.	Participants with titers (%)	GMT (95% CI)	No.	Participants with titers (%)		GMT (95% CI)
		≥8 (95% CI)			≥8 (95% CI)	≥128 (95% CI)	
MenA							
1M post-vac	97	95 (88.4 to 98.3)	123.7 (96.6 to 158.5)	91	100 (96.0 to 100.0)	100 (96.0 to 100.0)	7,307.5 (5,800.1 to 9,206.7)
1Y post-vac	94	41 (31.4 to 52.1)	7.2 (5.3 to 9.6)	88	99 (93.8 to >99.9)	98 (92.0 to 99.7)	2,215.8 (1,644.4 to 2,985.9)
MenC							
1M post-vac	97	99 (94.4 to >99.9)	234.6 (181.3 to 303.4)	91	100 (96.0 to 100.0)	95 (87.6 to 98.2)	866.0 (633.8 to 1,183.2)
1Y post-vac	92	64 (53.5 to 73.9)	14.6 (10.5 to 20.3)	88	58 (47.0 to 68.4)	33 (23.3 to 43.8)	20.6 (12.9 to 32.8)
MenW							
1M post-vac	97	100 (96.3 to 100.0)	459.9 (353.1 to 599.0)	91	100 (96.0 to 100.0)	99 (94.0 to >99.9)	2,997.3 (2,159.2 to 4,160.6)
1Y post-vac	94	88 (80.0 to 94.0)	56.1 (41.5 to 75.9)	88	70 (59.8 to 79.7)	63 (51.5 to 72.6)	126.0 (67.7 to 234.4)
MenY							
1M post-vac	96	100 (96.2 to 100.0)	374.7 (286.4 to 490.1)	92	100 (96.1 to 100.0)	98 (92.4 to 99.7)	2,258.7 (1,697.0 to 3,006.5)
1Y post-vac	94	90 (82.6 to 95.5)	53.1 (39.7 to 71.0)	87	91 (82.7 to 95.9)	83 (73.2 to 90.0)	352.1 (220.3 to 562.6)

hSBA/rSBA, serum bactericidal assay using human/rabbit complement; CI, confidence interval; GMT, geometric mean titer; M, month; post-vac, post-vaccination with four MenACWY-CRM doses; Y, year.